Drug Search Results
More Filters [+]

Ulevostinag

Alternative Names: Ulevostinag, mk-1454, mk1454, mk 1454
Latest Update: 2024-02-26
Latest Update Note: Clinical Trial Update

Product Description

Ulevostinag is a synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities. Upon intratumoral (IT) administration,ulevostinag binds to STING and activates the STING pathway, which promotes IKK-related kinase TANK-binding kinase 1 (TBK1) signaling and activates nuclear factor-kappa B (NF-kB) and interferon regulatory factor 3 (IRF3) in immune cells in the tumor microenvironment; this leads to the production of pro-inflammatory cytokines, including interferons (IFNs). Specifically, expression of IFN-beta (IFNb) enhances the cross-presentation of tumor-associated antigens by CD8alpha-positive and CD103-positive dendritic cells (DCs) to cytotoxic T-lymphocytes (CTLs). This results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Ulevostinag)

Mechanisms of Action: STING Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ulevostinag

Countries in Clinic: Australia, Austria, Brazil, France, Israel, Korea, Norway, Spain, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Head and Neck Cancer|Squamous Cell Carcinoma

Phase 1: Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Phase 2 Study in 1L HNSCC of IT MK-1454 / MK-3475 IV vs MK-3475 IV

P2

Temporarily not available

Head and Neck Cancer

2025-02-06

MK-1454-002

P2

Completed

Squamous Cell Carcinoma|Head and Neck Cancer

2022-09-30

MK-1454-001

P1

Completed

Lymphoma

2022-04-21

Recent News Events